Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -82.12% is 60% below its 5-year average of -51.24%, near the low end of its 5-year range (-82.12%–-26.92%).
As of the fiscal period ended Tuesday, June 30, 2026. 16.47% below its 12-month average of -70.50%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -82.12%.
RETURN ON EQUITY (ROE)
-82.12%
RETURN ON EQUITY (ROE) AVG TTM
-70.50%
RETURN ON EQUITY (ROE) AVG 3Y
-57.31%
RETURN ON EQUITY (ROE) AVG 5Y
-51.24%
RETURN ON EQUITY (ROE) AVG 10Y
-49.81%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-16.47%
CURRENT VS 3Y AVG
-43.29%
CURRENT VS 5Y AVG
-60.26%
CURRENT VS 10Y AVG
-64.85%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-95.47%
vs the sector median at left
Fate Therapeutics, Inc.
Market Cap
$271.00M
Return on Equity (ROE)
-82.12%
TTM Avg
-70.50%
3Y Avg
-57.31%
5Y Avg
-51.24%
Market Cap
$270.68M
Return on Equity (ROE)
-5.95%
TTM Avg
-61.29%
3Y Avg
-64.14%
5Y Avg
-41.58%
Market Cap
$271.35M
Return on Equity (ROE)
-4.68%
TTM Avg
-68.17%
3Y Avg
-57.88%
5Y Avg
-49.64%
Market Cap
$270.52M
Return on Equity (ROE)
-87.86%
TTM Avg
-58.47%
3Y Avg
-55.90%
5Y Avg
-119.72%
Market Cap
$270.30M
Return on Equity (ROE)
-124.83%
TTM Avg
-35.45%
3Y Avg
-17.31%
5Y Avg
-9.59%
Market Cap
$269.70M
Return on Equity (ROE)
-430.72%
TTM Avg
122.09%
3Y Avg
211.60%
5Y Avg
136.09%
Market Cap
$267.08M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.73M
Return on Equity (ROE)
-39.55%
TTM Avg
-28.46%
3Y Avg
-79.02%
5Y Avg
-63.95%
Market Cap
$264.44M
Return on Equity (ROE)
-184.27%
TTM Avg
-57.34%
3Y Avg
-61.84%
5Y Avg
-87.31%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $271.00M | -82.12% | -70.50% | -57.31% | -51.24% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $270.68M | -5.95% | -61.29% | -64.14% | -41.58% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $271.35M | -4.68% | -68.17% | -57.88% | -49.64% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.52M | -87.86% | -58.47% | -55.90% | -119.72% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.30M | -124.83% | -35.45% | -17.31% | -9.59% |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $269.70M | -430.72% | 122.09% | 211.60% | 136.09% |
| Scribe Therapeutics Inc. (SCTX)vs › | $267.08M | N/A | N/A | N/A | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | -39.55% | -28.46% | -79.02% | -63.95% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.44M | -184.27% | -57.34% | -61.84% | -87.31% |
| Palisade Bio, Inc. (PALI)vs › | $263.36M | -26.24% | -102.84% | -107.17% | -107.44% |
ROE
-82.1%
ROA
-48.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -82.12% |
| 2026-03-31 | -72.29% |
| 2025-12-31 | -65.79% |
| 2025-09-30 | -66.69% |
| 2025-06-30 | -65.63% |
| 2025-03-31 | -60.98% |
| 2024-12-31 | -58.44% |
| 2024-09-30 | -49.19% |
| 2024-06-30 | -44.26% |
| 2024-03-31 | -44.60% |
| 2023-12-31 | -43.68% |
| 2023-09-30 | -42.99% |
| 2023-06-30 | -48.33% |
| 2023-03-31 | -49.20% |
| 2022-12-31 | -58.21% |
| 2022-09-30 | -56.75% |
| 2022-06-30 | -43.71% |
| 2022-03-31 | -36.75% |
| 2021-12-31 | -31.25% |
| 2021-09-30 | -26.92% |
| 2021-06-30 | -28.19% |
| 2021-03-31 | -23.41% |
| 2020-12-31 | -45.10% |
| 2020-09-30 | -35.01% |
| 2020-06-30 | -24.57% |
| 2020-03-31 | -51.05% |
| 2019-12-31 | -40.10% |
| 2019-09-30 | -32.04% |
| 2019-06-30 | -59.63% |
| 2019-03-31 | -49.52% |
| 2018-12-31 | -41.50% |
| 2018-09-30 | -36.26% |
| 2018-06-30 | -109.93% |
| 2018-03-31 | -72.25% |
| 2017-12-31 | -55.65% |
| 2017-09-30 | -83.93% |
| 2017-06-30 | -66.01% |
| 2017-03-31 | -55.14% |
| 2016-12-31 | -45.74% |
| 2016-09-30 | -129.93% |
| 2016-06-30 | -134.54% |
| 2016-03-31 | -99.22% |
| 2015-12-31 | -78.85% |
| 2015-09-30 | -63.96% |
| 2015-06-30 | -55.79% |
| 2015-03-31 | -126.04% |
| 2014-12-31 | -91.33% |
| 2014-09-30 | -75.62% |
| 2014-06-30 | -62.72% |
| 2014-03-31 | -53.85% |
| 2013-12-31 | -41.09% |
